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Abstract
Introduction: Adrenocortical carcinoma is a rare malignancy with a poor prognosis and presents
with mass effects and less often with signs of hormone excess (approximately 60% of all
adrenocortical carcinoma’s). Hormonally active adrenocortical carcinomas most commonly secrete
cortisol while the co-secretion of multiple steroid hormones is rare.
Case presentation: We report the case of a 59 year-old woman with a medical history of
hyperaldosteronism due to a right adrenal adenoma. During follow up, she showed symptoms of
hypercortisolism and hyperandrogenemia and a rapid growth of the adrenal mass. She underwent
right adrenalectomy and the histology revealed the presence of an adrenocortical carcinoma.
Six months post-operatively being on treatment with mitotane, she was diagnosed of metastatic
disease to the liver. She underwent right hepatectomy and was started on systemic chemotherapy,
with no signs of tumour recurrence during the following six months.
Conclusion: The hormonal status should be carefully investigated in all cases of suspected
adrenocortical carcinoma, as the pattern of hormone secretion may be a clue to the malignancy of an
adrenal lesion. In addition, more data are needed to clarify the clinical and prognostic significance of
the combined production of all adrenocortical hormones affecting either the survival or the quality of
life of adrenocortical carcinoma patients.
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Adrenocortical carcinoma (ACC) represents a rare malig-
nancy accounting for 0.05-0.2% of all cancers with a poor
prognosis depending on the stage of the disease and the
completeness of the resection [1,2]. Approximately 60% of
ACC’s are hormone-secreting and the steroid profile often
displays a wide variety of steroids in ACCs, which may be
used as tumour markers to detect metastastic disease. Most
commonly ACC secretes cortisol while the combined
secretion of all adrenocortical hormones is quite rare with
unknown either clinical or prognostic significance [3-5].
Case presentation
In September 2006, a 59-year old Greek Caucasian woman
presented to her local hospital due to a hypertensive crisis
(blood pressure: 170/100 mmHg). Endocrinological
investigation, revealed marked hypokalemia (serum
potassium: 2.7 mEq/l), suppressed renin levels, increased
aldosterone levels with an aldosterone/renin ratio >30,
findings suggestive of primary hyperaldosteronism. How-
ever, cortisol, catecholamines or other hormones were not
measured, despite the fact that she was a hypertensive
patient. Abdominal CT scan revealed the presence of a
solid enlargement of the right adrenal (max diam. 2 cm)
with radiological characteristics of benign adenoma while
attenuation value and wash-out procedure were not
performed, making the diagnosis of “benign adenoma”
somewhat arbitrary. The patient was started on spirono-
lactone treatment, with gradual improvement of her blood
pressure and serum potassium levels and was suggested of
surgical excision of the adrenal adenoma, which she
denied.
One-year later, she was referred to our department with
signs of sustained hypertension despite spironolactone
treatment, mild hirsutism, irregular vaginal bleeding,
increased body weight and central adiposity. Abdominal
CT and MRI scan showed a large right adrenal mass
(6.1 × 6.5 × 5.5 cm), with morphological characteristics
suggestive of carcinoma (increased attenuation value of the
lesion, low relative enhancement washout) (Figure 1a,b).
Hormonal evaluation showed increased 24-hour urinary
free cortisol excretion, loss of circardian rhythm of cortisol,
cortisol non-suppression in dexamethasone test and
undetectable ACTH levels, suggestive of hypercortisolism
of adrenal origin. In addition, hyperandrogenemia was
found, reflected in increased androgen levels, in particular
total and free testosterone, Δ4 androstenedione and 17 OH
progesterone. (Table 1) Despite being on spironolactone
treatment, the patient had increased aldosterone levels
(17.8ng/dl,normal 0.8-13),whilereninwas withinnormal
values (3.6, normal 1.5-5.7 ng/ml/h). She underwent right
adrenalectomy and histology confirmed the diagnosis
of ACC (Figure 2) with a Ki-67 proliferation index of
approximately 25%. The patient was subsequently started
on mitotane treatment. Despite the fact that scintigraphy
was not performed postoperative normalization of the
hormonal profile was indicative of the multi-hormonal
secretion by the ACC (Table 1).
Six months after surgery, she showed signs of hypertension
recurrence accompanied by hypokalemia (serum potas-
sium: 2.9 mEq/l) and hypernatremia (serum sodium:
150 mEq/l). Abdominal CT scan revealed a metastatic
lesion in the right hepatic lobe (diam 2.6 cm) (Figure 3).
The patient was referred to an oncology hospital, where
she underwent right hepatectomy and was started on
systemic chemotherapy, with no signs of tumour recur-
rence in the following six months according to the
hospital’s medical report. The Pathology Department
which analyzed the hepatic tumor histology confirmed
that it was an ACC metastasis. However, data regarding the
Figure 1a & b. Abdominal CT scan showing a large right adrenal mass (max. diam 6.5 cm).
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Discussion
We report a patient with ACC and abnormal secretion
of all adrenocortical hormones, namely glucocorticoids,
mineralocorticoids and androgens. Although she was
initially presented with hyperaldosteronism and radiolo-
gical characteristics suggesting a benign adenoma, during a
rather short-time follow up, she showed hypersecretion of
all adrenal hormones, in parallel with an aggressive
behavior of the ACC manifested by the rapid growth of
the adrenal tumour and hepatic metastasis.
In our case, only aldosterone and renin levels were
measured during her initial evaluation, despite the fact
that other hormones such as cortisol and catecholamines
should be measured in a hypertensive patient. However,
quantitative and/or qualitative changes in hormone
secretion by an adrenal tumour are not uncommon [6].
It has been reported that ACC cases produce hormones
and the steroid profile often displays a wide variety of
steroids in ACCs, which may be used as tumour markers to
detect metastastic disease. Most commonly ACC produces
cortisol (50%), followed by androgens while aldosterone
production is quite rare (<2%) [4]. Less frequently, ACC
produces combined hormonal syndromes most com-
monly cortisol with androgens (up to 46.7% of cases)
while the combined hypersecretion of all adrenocortical
hormones occurs rarely [3-5]. Moreover, increased cortisol
production has been characterized as a poor prognostic
factor for ACC and the overall prognosis seems to be
improved with o,p’DDD treatment [7] However, there are
not any certain clues regarding the natural course and the
clinical significance of increased co-secretion of all steroid
hormones in ACC cases [3-5].
In addition, the temporal development from a 2 cm to a
6 cm tumour being malignant has rarely been reported.
Most studies of incidentalomas have a portion of patients
found to suffer from ACC, but their tumours are large (at
least >4 cm) or grow rapidly (5-15 cm in 3 months) but
not one which seem to have a quite modest growth rate
(3-fold) in 1 year, as the present case. Our case in support
of other cases and studies indicate that the growth rate of
an ACC is largely unknown and varies widely between
different patients due mostly to the fact that they are
treated when they are found and not followed as the
present case.
Conclusion
In conclusion, the hormonal status should be carefully
investigated in all cases of suspected ACC, as the pattern of
hormone secretion may be a clue to the malignancy of an
adrenal lesion [8]. In addition, more data are needed to
Figure 3. Abdominal CT scan showing a metastatic lesion in
the right hepatic lobe (max. diam 2.6 cm).
Table 1. Hormonal profile of the patient with ACC before and after
surgical treatment
Hormonal profile Before After Normal
range
Plasma renin activity (PRA) (ng/ml/h) 0.1 5.3 1.5-5.7
Aldosterone (ng/dl) 39 12.9 0.8-13
Aldosterone/Renin ratio 390 2.4
Basal serum cortisol 8 am-12 pm (ug/dl) 13.5-12 12 6.2-19.4
Urinary free cortisol (ug/24hrs) 146 65 20-130
Plasma ACTH (pg/ml) <1 24.5 5.0-60
Serum testosterone (ng/dl) 229 5.91 6.0-82
Serum free testosterone (pg/ml) 0.4 0.3 0.3
Serum Δ4-androstendione (ng/ml) 7.7 2.3 0.3-3.3
Serum 17-OH progesterone (ng/ml) 3.4 0.6 0.2-3.3
Serum DHEAs (ug/dl) 61 40 35-430
Figure 2. Macroscopic findings of the surgically removed
tumour.
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prognostic significance of the combined production of all
adrenocortical hormones affecting either the survival or
the quality of life of ACC patients.
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